Lyell Immunopharma (LYEL) Operating Leases (2020 - 2026)

Lyell Immunopharma's Operating Leases history runs 7 years deep, the most recent figure standing at $48.9 million for Q1 2026.

• In Q1 2026, Operating Leases changed 0.0% year-over-year to $48.9 million; the TTM figure through Mar 2026 stood at $48.9 million (changed 0.0% YoY), while the FY2025 annual figure was $41.9 million, down 17.79% from the prior year.
• Operating Leases came in at $48.9 million for Q1 2026 at Lyell Immunopharma, up from $41.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $67.6 million in Q2 2022 to a low of $41.9 million in Q4 2025.
• A 5-year average of $56.8 million and a median of $56.9 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases climbed 9.84% in 2022 and declined 17.79% in 2025, its largest moves.
• Lyell Immunopharma's Operating Leases stood at $63.2 million in 2022, then dropped by 9.93% to $56.9 million in 2023, then dropped by 10.37% to $51.0 million in 2024, then dropped by 17.79% to $41.9 million in 2025, then advanced by 16.53% to $48.9 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $48.9 million, $41.9 million, and $44.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison